2000
DOI: 10.1002/(sici)1521-3773(20000117)39:2<290::aid-anie290>3.0.co;2-1
|View full text |Cite
|
Sign up to set email alerts
|

NMR Studies of Ligand Binding to Dihydrofolate Reductase

Abstract: Unique capabilities are offered by NMR spectroscopy for probing specific interactions of enzymes with substrates and substrate analogues, for characterizing the multiple conformations of the complexes, and for measuring rates of a wide range of dynamic processes. The most extensive studies of this type have been directed at complexes formed by dihydrofolate reductase with antifolate drugs and are described in this review.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
16
0

Year Published

2002
2002
2019
2019

Publication Types

Select...
6
3

Relationship

3
6

Authors

Journals

citations
Cited by 51 publications
(16 citation statements)
references
References 101 publications
(201 reference statements)
0
16
0
Order By: Relevance
“…These antifolate drugs often bind to the protein with large positive cooperativity in the presence of the coenzyme NADPH. 30 In the case of the antibacterial drug trimethoprim (TMP; trimethoprim(2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine)), the cooperative binding has been implicated directly in the specificity of drug binding to bacterial DHFRs when compared to mammalian DHFRs. 31 Another ligand, the tetrahydrofolate analogue 5-formyl-5,6,7,8-tetrahydrofolic acid (folinic acid), binds to DHFR with strong negative co-operativity in the presence of NADPH: 32 similar negative co-operativity binding effects have important implications in the control of product release in the enzyme reaction mechanism.…”
Section: Introductionmentioning
confidence: 99%
“…These antifolate drugs often bind to the protein with large positive cooperativity in the presence of the coenzyme NADPH. 30 In the case of the antibacterial drug trimethoprim (TMP; trimethoprim(2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine)), the cooperative binding has been implicated directly in the specificity of drug binding to bacterial DHFRs when compared to mammalian DHFRs. 31 Another ligand, the tetrahydrofolate analogue 5-formyl-5,6,7,8-tetrahydrofolic acid (folinic acid), binds to DHFR with strong negative co-operativity in the presence of NADPH: 32 similar negative co-operativity binding effects have important implications in the control of product release in the enzyme reaction mechanism.…”
Section: Introductionmentioning
confidence: 99%
“…Such drugs act by inhibiting the enzyme in parasitic or malignant cells. There have been several studies aimed at investigating the speci®city of the ligand binding (see for example Roth & Cheng, 1982;Baccanari & Kuyper, 1993) and extensive structural information has been obtained on a number of DHFR complexes from different species using NMR and X-ray crystallography (reviewed by Blakley, 1985;Freisheim & Matthews, 1984;Feeney, 1990Feeney, , 1996. For the enzyme from Escherichia coli, there are high-resolution crystal structures available on the enzyme alone (Bystroff & Kraut, 1991) several binary complexes Kuyper et al, 1982;Matthews et al, 1985a,b;Bystroff et al, 1990;Warren et al, 1991;Reyes et al, 1995;Lee et al, 1996;Sawaya & Kraut, 1997) and ternary complexes (Bystroff et al, 1990;Sawaya & Kraut, 1997).…”
Section: Introductionmentioning
confidence: 99%
“…All structurally determined, chromosomally encoded DHFRs are single domain proteins containing an eight‐stranded mixed β‐sheet, which is flanked by two α‐helices on either side (Fig. 1) (Sawaya and Kraut 1997; Feeney 2000). DHFRs are organized into two subdomains, the adenosine‐binding domain, which binds the adenosine portion of NADPH, and the loop domain, which is dominated by three loops, namely the M20 loop, the βF–βG loop, and the βG–βH loop.…”
mentioning
confidence: 99%